THE IMPLEMENTATION OF NANOTECHNOLOGY AND ARTIFICIAL INTELLIGENCE IN CRISPR DEVELOPMENT
Keywords:
Genome engineering, Guide RNA (gRNA), Base editing, CRISPR-Cas sysytems, Gene therapy, Artificial IntelligenceAbstract
Genome engineering has made remarkable strides, evolving from DNA-binding proteins such as zinc fingers and transcription activator-like effectors to CRISPR–Cas systems. CRISPR technology has revolutionized the field through its simplicity and ability to target specific genome regions via guide RNA and Cas proteins. Progress in CRISPR tools—CRISPR nucleases, base editors and prime editors—has expanded the toolkit to induce targeted insertions or deletions, nucleotide conversions and a wider array of genetic alterations. Nevertheless, variations in editing outcomes across cell types and unintended off-target effects still present substantial hurdles. Artificial intelligence (AI), which has seen rapid advances, provides high-level solutions to these problems. By leveraging large datasets from diverse experiments, AI enhances guide RNA design, predicts off-target activities and improves editing efficiency. In addition, AI aids in discovering and designing novel CRISPR systems beyond natural limitations. These developments provide new modalities essential for the innovation of personalized therapies and help to ensure efficiency, precision and safety. Here we discuss the transformative role of AI in advancing CRISPR technology. We highlight how AI contributes to refining nuclease-based editing, base editing and prime editing. Integrating AI with CRISPR technology enhances existing tools and opens doors to next-generation medicine for gene therapy.
References
(1) Bibikova, M., Beumer, K., Trautman, J. K. & Carroll, D. Enhancing gene targeting with designed zinc finger nucleases. Science 300, 764–764 (2003)
(2) Porteus, M. H. & Baltimore, D. Chimeric nucleases stimulate gene targeting in human cells. Science 300, 763–763 (2003).
(3) Kim, H. & Kim, J.-S. A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15, 321–334 (2014).
(4) Kim, Y. et al. A library of TAL effector nucleases spanning the human genome. Nat. Biotechnol. 31, 251–258 (2013).
(5) Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143–148 (2011).
(6) Cho, S. I. et al. Engineering TALE-linked deaminases to facilitate precision adenine base editing in mitochondrial DNA. Cell 187, 95–109 e26 (2024).
(7) Lim, K. Mitochondrial genome editing: strategies, challenges, and applications. BMB Rep. 57, 19–29 (2024).
(8) Lim, K., Cho, S. I. & Kim, J. S. Nuclear and mitochondrial DNA editing in human cells with zinc finger deaminases. Nat. Commun. 13, 366 (2022).
(9) Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
(10) Cho, S. W., Kim, S., Kim, J. M. & Kim, J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230–232 (2013).
(11) Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
(12) Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
(13) Eid, A. & Mahfouz, M. M. Genome editing: the road of CRISPR/Cas9 from bench to clinic. Exp. Mol. Med 48, e265 (2016)
(14) Adli, M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 9, 1911 (2018).
(15) Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824–844 (2020).
(16) Jang, H. K., Song, B., Hwang, G. H. & Bae, S. Current trends in gene recovery mediated by the CRISPR–Cas system. Exp. Mol. Med. 52, 1016–1027 (2020).
(17) Healey, N. Next-generation CRISPR-based gene-editing therapies tested in clinical trials. Nat. Methods 30, 2380–2381 (2024).
(18) Gaudelli, N. M. et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).
(19) Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
(20) Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729 (2016).
